The University of Liverpool researchers create a low-cost, handheld AI-powered blood test to detect Alzheimer's biomarkers, enabling earlier diagnosis and global accessibility.
The BlueInvest fund today allocated the first of an available €75 million to two projects working against food insecurity - announcing the names at a BlueInvest Day event.
New vaccine data from Israel suggests that the double-dose of Pfizer is performing at the expected rate of 95% efficiency - with the possibility that it is performing even better than that being further investigated.
Researchers have found that neurofeedback, or 'brain training', may be an effective treatment for individuals with post-traumatic stress disorder (PTSD).
In response to the AstraZeneca feud, EU officials are creating a "transparency mechanism" for vaccine exports - which would indirectly hold companies accountable for fulfilling their agreed contracts.
The company announced that their current vaccine can handle the South African COVID mutation - with plans to create an "additional booster dose" to see if they can create specific protections against emerging variants.
The UK will offer its world-leading genomics expertise to identify new variants of the COVID-19 virus to countries who do not have the resources to do so.
Researchers are looking into Twitter whistle-blowers who raised concerns about suspicious 'pneumonia' cases, one month before the Chinese Government announced the existence of COVID-19.
Online courses have popped up in many different sectors but can they deliver what they promise, and how do attendees ensure they get the best results from enrolling on one of these courses?
Tomorrow (26 January) the COVID 'O' meeting is expected to be a moment of decision-making about border policy, as the more infectious South African and Brazilian COVID mutations continue to circulate.
Romy Rawlings, Commercial Director at Vestre Ltd, discusses how COVID-19 has acted as a catalyst for transforming urban spaces, and why introducing parklets could be the way forward.
EU leaders are investigating why AstraZeneca are not following through with the pre-agreed number of vaccines for the Member States - taking a 60% cut to the expected amount.
